After thinking he just had a stubborn sinus infection that wouldn't go away, Brian McNamara was told he had an ultra-rare ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Pathologist Michael Roehrl is part of a multidisciplinary team that evaluates and treats hundreds of people with neuroendocrine tumors every year. At Memorial Sloan Kettering Cancer Center, our ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

It can be difficult to cope with a neuroendocrine cancer and its treatment. People often think they have an idea of what having cancer is like, but neuroendocrine cancer is different from other ...

18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a strong prognosis predictor for neuroendocrine tumors, according to new research from scientists at the Rigshospitalet, ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new ...

But when his symptoms persisted, he went to the doctor and had multiple tests, scans, and biopsies which led him to discover he has Nasopharyngeal Small Cell Neuroendocrine Carcinoma, an ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...